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Abstract
Introduction: Zinc chelators were shown to facilitate some opioid-withdrawal signs in animals. Zinc deficiency,
which affects more than 15 % the world’s population, is also common among opioid consumers and opioid-treated
animals exhibit misbalances of zinc distribution.
Aim: The present study focuses on how zinc ions interfere with opioid dependence/addiction and analgesia, trying
to preliminary discuss if zinc supplementation in opioid-users should be recommended in order to reduce the risk
of addiction.
Methods: All relevant literature was searched up to April 2015. The search was performed using the term “zinc”
plus combinations of following terms: “opioid receptors”, “opioid” or representatives of this class, “addiction”,
“dependence”, “analgesia”, and “pain”. Human, animal, in vitro studies and reviews were including.
Results: Both human and animal studies revealed decreased serum zinc under opioid-administration conditions,
attributed mainly to increased urinary elimination (humans) or redistribution (animals). Moreover, animal studies
revealed decreased brain zinc levels in morphine-treated animals, with increased zinc hepatic levels, but also an
enhancement of endogenous opioid system activity and a possible reduction of morphine withdrawal by zinc. In
vitro studies revealed reduction of opioid ligands binding to receptors by zinc. However, the very few in vivo animal
studies on opioid analgesia revealed controversial results, as zinc demonstrated clear analgesic effect, but zinc
associated to opioids doesn’t result in a potentiation of the analgesic effect.
Conclusion: Zinc dietary supplementation in patients treated with opioids for cancer-related chronic pain should
be considered, due to the high incidence of zinc deficiency, also well-documented in opioid consumers. The low
toxicity of orally-administered zinc also pleads for this idea. The main contra-argument to zinc administration in
opioid-treated persons is related to the way zinc influences opioid-induced analgesia.
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Introduction
Zinc, the second most abundant trace element in the
human body (after iron) [1], plays mainly catalytic and
structural roles [2]; as a co-factor of Cu-Zn superoxide
dismutase, it is important for the anti-oxidant defence
[3]. Zinc finger proteins acting as transcription factors
regulate gene expression [4]. Within the central nervous
system (CNS), zinc acts at the post-synapse level and
influences synaptic plasticity, hormone release, and nerve
impulse transmission [5–7], regulates post-synaptic pro-
teins [8] and has important roles in the formation and
maintenance of the structure of the post-synaptic density,
a proteins network connecting the neurotransmitter
receptors to the intracellular signalling system and to the
cytoskeleton [9, 10].
The brain is one of the organs with high Zn2+ concen-
tration, as it contains approximately 1.5 % of the
estimated 2 to 3 g of zinc in the human body. Brain-zinc
is non-uniformly distributed: the olfactory bulb has the
highest level, followed by the frontal and parietal corti-
ces, the striatum and the hippocampus; the lowest levels
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are in the medulla and thoracic spinal cord [11]. In the
hippocampus, Zn2+ concentrations can reach up to
0.3 mM in the mossy fiber boutons of neurons extend-
ing from the dentate gyrus to neurons in the hilar and
CA3 fields [12]. Distribution vary with the age: in rats,
at birth, cerebellum has the highest zinc level; within
time, the hippocampus and the cortex levels increase
[13, 14]. Neuronal Zn2+ is either bound to various
proteins (over 90 %, with structural or catalytic roles
and roles in transcription factors and related proteins)
or free (mainly localized within the vesicles of zinc-
dependent glutamatergic neurons) [15].
Severe deficiency is rare, but mild to moderate zinc
deficiency is widespread. Zinc deficiency affects more
than 15 % of world population and the prevalence of
inadequate intake varies from 7.5 % in high-income
regions to 30 % in South Asia [16, 17]. Zinc intake is
lower than recommended in more than 75 % of preg-
nant women [18]. Zinc is a type 2 essential nutrient
[19], as deficiency symptoms are rather nonspecific;
response to repletion occurs very fast [20]. Deficiency
determines growth retardation, male hypogonadism,
delayed wound healing and cell-mediated immune
dysfunction [21]. Reduced zinc is also associated with
DNA damage, increased inflammatory status [22, 23]
and represents a predisposing factor for malignant tu-
mours development [24]. Some deficiency-associated
conditions are partially explained considering zinc’s
role as a co-factor of enzymatic systems involved in
nucleic acids replication, protein synthesis, and anti-
oxidant defence. Disorders mainly related with CNS
impaired function (behavioural changes, depression,
emotional instability, anxiety, aggresivity, irritability,
socializing deficits, impaired memory and learning,
neurosensory alterations, anorexia etc.) are frequently
associated with zinc deficiency in both humans and
animal models [25, 26]. It is debatable, at least in case of
some of these conditions, if decreased zinc is a conse-
quence or a cause. Low zinc levels have been reported in
autism spectrum disorders, attention deficit hyperactivity,
schizophrenia, and spinocerebellar ataxia type 2 [27],
underlining its importance in brain functioning. Under
moderate zinc deficient diet in rats, brain zinc is main-
tained within normal limits, due to increased uptake [28],
following transporters adaptation: the expressions of
metallothionein-I and ZnT-1 are decreased, and that of
LIV-1 is increased [29]; even so, subclinical deficiency af-
fects human brain function [30].
Zinc salts are relatively nontoxic, particularly if taken or-
ally. Symptoms including nausea, vomiting, epigastric
pain, lethargy, and fatigue appear ‘at extremely high
intakes (almost 100 folds above the recommended dietary
allowance – 15 mg elemental zinc daily). Doses of 100-
300 mg zinc daily, which are high above recommended,
determine induced copper deficiency, anaemia and neu-
tropenia, immune dysfunction and increased low-
density vs. high density lipoproteins ratio [31–33]. Zinc
toxicity is also manifest at the CNS level, where zinc
has an additional role in the death of seizures-damaged
neurons [34]. In Alzheimer’s disease, zinc has been
shown to facilitate beta-amyloid aggregation [35]. In
Parkinson disease, excessive hair zinc levels [36] and in-
creased zinc exposure [37] are reported, but serum zinc
is decreased [38]; substantia nigra zinc levels were
found to gradually increase in rat model of parkinson-
ism [39].
A study of Larson et al., [40], evidenced increased
withdrawal jumpings, but with no influence on acute
dependence in conditions of zinc-chelator administra-
tion in mice. This is in accordance with preliminary data
of ours showing a reduction of morphine dependence in
rats by zinc chloride (ZnCl2) (dose-dependent) [41]. A
possible reasonable, yet partial explanation for these re-
sults can be given considering zinc ions effect of redu-
cing μ-opioid agonists’ binding to receptors [42, 43].
Taking into consideration zinc ability to reduce
morphine-dependence intensity and the enhancement of
withdrawal manifestations by zinc-chelators, we have
formulated the hypothesis that zinc supplementation
may reduce the risk of addiction in cancer-patients
treated with opioids for chronic pain. The idea is rein-
forced by the low levels of zinc evidenced in opioid users
[44–47] and the low toxicity of zinc is also in favour of
this. The main contra-augment is that zinc, in spite of
having well-documented analgesic action [48–54], may
reduce the opioid analgesic efficacy, due to affecting
binding affinity to receptors.
In this context, the present study aims to document,
on the basis of the existent literature, the effect of zinc
and zinc misbalances on opioid addiction, dependence
and analgesia, trying to evidence and discuss if zinc
supplementation in opioid users may be (or not) benefi-
cial, in order to reduce the risk and/or the severity of
addiction.
Methods
All relevant literature (Scopus, Medline, and ProQuest
databases) was searched up to May 2015. The search
was performed using the term “zinc” plus combinations
of following terms: “opioid receptors”, opioid or repre-
sentatives of this class, “addiction”, “analgesia”, “algesia”
and “pain”.
We have included articles (clinical studies, animal stud-
ies, in vitro studies and reviews – full-text or abstracts)
containing information about:
1. zinc homeostasis in opioid consumers and opioid-
treated animals compared to opioid-free individuals;
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2. 1. the influence determined by zinc ions or zinc
deficiency on the intensity of opioid-binding to specific
and non-specific receptors (in vitro studies);
2. 2. the influence determined by zinc ions or zinc de-
ficiency on the activity level of endogenous opioidergic
system (animals and human studies);
3. the influence determined by zinc administration and
zinc deficiency in animal models of opioid dependence
and on the intensity of human opioid-addiction;
4. the influence of zinc ions or zinc deficiency on
human and animal pain perception under opioid-free
and opioid administration conditions.
Notes to the editors or comments were not consid-
ered. Search-retrieved articles which did not contain in-
formation on the mentioned issues were not considered.
Results of the initially-retrieved articles suggested
some further searching strategies, which were applied to
collect more relevant information. Some other relevant
findings retrieved by initial searches are also presented
when considered relevant, even though provided data do
not perfectly fit initially-searched information. At each
results sub-chapter, such things are being detailed.
Information on zinc-containing transcription factors,
zinc-containing enzymes or zinc-finger proteins involve-
ment on the addictive process or opioids mechanism of
action was not considered.
Zinc ions and zinc deficiency influence on neurotrans-
mitters important for development and maintenance of
the addictive process (such as dopamine, glutamate etc.)
or other mechanisms involved in drug addiction are not
included, giving the complexity of such a topic and the
difficulty of data interpretation.
Results
The initial search-results provided the below-mentioned
number of articles: 1. zinc + opioid: 133 articles; 2. zinc +
opioid + receptor: 57 articles; 3. zinc + pain: 531 articles; 4.
zinc + analgesia: 28 articles; 5. zinc + algesia: 34 articles;
6. zinc + addiction + opioid: 6 articles; 7. zinc + depend-
ence + opioid: 7 articles.
Upon consulting the retrieved articles, only few of the
retrieved search results were found to contain the infor-
mation. Some of the articles were retrieved following at
least two of the search terms combinations.
Results of the initially-retrieved articles suggested some
further searching strategies, which were applied to collect
more relevant information (for instances, we have used
the names of the substances belonging to opioids class).
When considered relevant for the topic, additional in-
formation from the displayed articles is also presented at
the results section. For instance, information about copper
(a metallic trace elements to which zinc manifest a certain
degree of biological antagonism) and metallothioneins (a
family of cysteine-rich proteins strongly involved in both
zinc and copper metabolism [55]) levels following opioids
administration are also presented, as well as the data on
trace elements content of different opioid preparations.
The number of articles considered relevant is summarised
at the beginning of each sub-chapter.
Zinc misbalances in conditions of opioid administration
There are many humans studies reporting low zinc levels
due to alcohol consumption [56–61]; studies about zinc
levels in case of nicotine addiction or smokers are scarce
and reveal non-concordant data [62–65]. There are no
studies on microelements status in case of psychostimu-
lants or cannabis administration in particular.
Human studies
Upon refining the articles retrieved by the initial searches,
we have found five studies which evaluated zinc status in
persons consuming opioids (controlled-users or meeting
diagnosis for opioid addiction), all stating either reduced
zinc levels or increased elimination of zinc. Results
present the concentration of zinc status in different body
fluids (serum, plasma, cerebrospinal fluid), before, during
and after the treatment (immediately, long-term after),
but not zinc level in different organs. The main findings
and their relevance to the evaluated topic are presented
and commented below. Additional data considered rele-
vant (such as copper status and information regarding
zinc presence in opioid preparation) are also revealed in
the below paragraphs.
Low zinc serum concentrations were reported in
heroin consumers upon admission for treatment, with a
slight tendency to increase during detoxification, yet not
reaching the levels in controls [44]. In patients diag-
nosed with heroin addiction, zinc deficit appears to be
correlated with the abuse period in case of heroin addic-
tion [45] and low zinc plasma is accompanied by low
intraerythrocytic zinc and by increased plasma and
intraerythrocytic copper [46]. In case drug-free patients
with heroin-addiction documented in the past, zinc con-
centration in the cerebrospinal fluid (CSF) of is lower
than in controls, but generally within normal limits [47].
It is worth mentioning that the heroin samples on the
illegal market, when analysed for the various metals con-
tents, were shown to present variable amounts of zinc,
but these traces have little contribution to product’s tox-
icity and to the trace elements intake [66, 67] and they
probably appear from the metallic container used in the
processing/cutting stage [68]. During methadone detoxi-
fication treatment for opioid addiction, zinc elimination
is strongly increased, while copper elimination is slightly,
but significantly decreased [69].
One of the problems with human studies is that not all
of them consider the type of opioid drug, or the possible
association with other consumed drugs or co-existent
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pathology; also, most of them fail to evidence the corre-
spondences between abuse period, addiction severity and
decreased zinc status and only one study [45] states that
there is an association between the period of heroin con-
sumption and the severity of zinc deficit. One of the stud-
ies makes little separation between heroin users and
patients with mixed addiction (heroin + other drugs of
abuse) [46].
Another problem is that these studies do not evidence
if zinc deficiency is an effect of drug-taking or an associ-
ated condition in opioid-users. Feeding habits are not
being considered, while malnutrition is common among
people consuming drugs of abuse or alcohol [70], espe-
cially in women [71]. Malnutrition partially explains re-
duced zinc levels in case ethanol-consumption [58, 59].
Decreased CSF zinc in drug-sober former heroin users
(even if concentration is generally within normal limits)
[47] pleads that zinc deficiency in opioid users is rather
a consequence of the alimentation habits, but evidences
of increased urinary zinc elimination in patients taking
methadone [69] as substitution therapy suggests that
opioid-administration also has a specific role in this.
Clinical studies should be interpreted taken into consid-
eration the association between decreased appetite and
decreased zinc. Malnutrition can be regarded as a cause
of zinc deficiency, but, on the other hand, low level of
zinc represents a cause of the lack of appetite, as docu-
mented by animals studies presented below [72, 73].
Between zinc and copper there is a certain degree of
antagonism at the level of biological actions [74]; it ap-
pears that zinc deficiency has better conditions to more
evidently manifest in opioid consumers, as decreased
zinc is accompanied by increased serum and intraery-
throcytic copper in heroin users [46] and given that cop-
per urinary elimination is decreased under methadone
maintenance treatment [69].
Animal studies
We have found four relevant researches on the influence
determined by opiods administration on zinc status or
metallothioneins levels in animals. Two of them refer to
zinc levels following morphine administration in ro-
dents; one of them considers mainly zinc and metal-
lothioneins liver level and the nature of its mediation,
the other considers zinc levels in several organs and
serum zinc concentration. Some aspects regarding me-
tallothionein levels following morphine administration
(presented by one of the two mentioned articles and by
another article from those displayed by the initial search)
was considered relevant for our topic. The forth study
that we have included takes into consideration the influ-
ence of a δ-opioid receptor’s specific agonist on zinc
levels of different brain regions. Main findings are ex-
posed below, and briefly commented.
Morphine decreases serum zinc and increases liver
citosolic zinc and metallothionein levels in rats. While
morphine’s effect on liver metallothionein level appears
to be mediated mainly by morphine’s action at receptors
level (being antagonized by naloxone), liver zinc accumu-
lation does not recognize this mechanism, as naloxone
does not alter it; glucocorticosteroids and β-adrenergic
mediation seem to be at least partially responsible for
morphine effect of increasing zinc liver levels, as their
blockade (with RU486 and respectively labetalol) dimin-
ishes it [75].
Interestingly, in a study investigating the effect of
escalating doses of morphine in mice, increased zinc
serum concentration and decreased liver zinc level were
found; the brain zinc level was found decreased, as well
as lungs and kidneys zinc levels, while spleen, heart and
muscles zinc levels were found increased [76].
δ-opioid receptor’s agonist also decrease brain zinc level:
(D-Pen2, D-Pen5)enkephalin (δ agonist) intracerebroven-
tricular administration decreases parietal cortex, hippo-
campus and striatum Zn2+ contents. The effect is time-
and dose-dependent and it is antagonized by naloxone
pre-treatment [11].
Animal studies evidenced decreased brain zinc levels
under opioid-administration conditions, which is diffi-
cult to document in case of humans (human studies
only considered CSF, where zinc was found decreased
in sober patients previously diagnosed with heroin-
addiction [45]) and showed that one possible cause for
zinc deficiency under opioid-administrating conditions
is its re-distribution, mainly to the liver [75].
Table 1 summarizes the results of both human and
animal studies.
Zinc ions actions and zinc deficit effects on opioid
system
Zinc ions actions and zinc deficit effects on opioid
binding to receptors (in vitro studies)
A very important component of zinc actions on mecha-
nisms involved in drugs addiction takes place at the level
of the opioid receptors. There are four studies reporting
the inhibition of both agonists (endogenous and exogen-
ous) and antagonist’s affinity to opioid receptors and two
studies proving the increase of naloxone binding to opioid
receptors in conditions of zinc-deficiency (chelators-use
or following zinc-deficient diet). Additional information
regarding possible interactions between zinc or zinc defi-
ciency and the affinity of opioids to the non-opioid spe-
cific σ-receptors is revealed by other two studies. Table 2
summarizes the results.
Physiologic zinc concentration inhibits the binding of
specific agonists to μ-receptors; δ and κ receptors were
relatively insensitive to this type of inhibition [42]. How-
ever, micromolar zinc concentrations inhibit the binding
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of enkephalin (specific δ-agonist) to receptors [43] and
zinc ions determine a total blockade of the stereospe-
cific δ-agonist 3H-met-enkephalinamide (2-D-ala-5-L-
methionine) receptor-binding in synaptic hippocampus,
cerebral cortex and basal ganglia membranes in rats, at
in vitro concentrations compatible with endogenous
zinc level in the mentioned structures. One more re-
search [77] proves the inhibition determined by zinc
ions on ligand-binding to μ-receptors and determines
the aminoacids in the receptor’s structure which are
responsible for it. This δ-agonists binding inhibition
involves a decrease in both receptor affinity and the
number of binding sites [78] and is due to the inter-
action of zinc with essential SH-groups in the opiate
receptor structure. From the mentioned brain sites, it
is especially the hippocampus which has high zinc
content, almost exclusively localized in the giant bou-
tons of the mossy fibers [79].
The σ-receptors were considered opioid receptors,
but pharmacological tests showed that they are acti-
vated by drugs (such as phencyclidine or haloperidol)
completely unrelated to the opioids and σ1 receptor
has no structural similarity to the opioid receptors
[80]. However, many opioids act as σ-agonists, pent-
azocine being one of the most potent σ-receptors li-
gands [81]. Stimulation of the zinc-containing mossy
fibers in the hilar hippocampus region decreases the
specific binding of (+)-[3H]pentazocine to σ-sites, un-
affected by metallothionein peptide 1 (a specific zinc
chelator), suggesting that zinc deficit has little effect
on signalling through this receptor type [82]. However,
increasing the free zinc ions concentration is an essen-
tial stage of the opioid-signalling inhibition via σ1-re-
ceptors and μ-receptors interaction, as shown by very
recent findings [83].
Zinc ions inhibit the specific binding of [3H]naloxone
(μ-receptors antagonist) to receptors in the rats hippo-
campus, cortex, midbrain and striatum (dose-dependent
manner). The half maximal inhibitory concentration
(IC50) is close to 30 μM, similar to the physiological zinc
concentration in to extracellular brain environment.
Inhibition is due to a decrease in receptor affinity, the
number of binding sites being un-affected and it is
reverted by histidine, which most probably acts as a chela-
tor, as histidine alone has no effect on receptor affinity or
the binding sites number [84]. This is in accordance with
the proof that the [3H]-naloxone (1nM) binding to iso-
lated brain membranes is increased in zinc deficient ani-
mals compared to ad libitum fed controls, while the
weight restricted animals exhibit intermediate values [72].
zinc ions actions and zinc deficit effects on endogenous
opioidergic system activity
We have found just three relevant animal studies (and
no relevant human studies) on zinc ions and zinc defi-
ciency effect on the activity degree of endogenous opioid
system. If there are clear, concordant data revealed by in
vitro studies indicating the reductions of opioid binding
to receptors by zinc, there are studies revealing that zinc
determines important increases in the degree of activity
of endogenous opioid system, while zinc deficiency de-
termines opposite effects.
Table 1 A table with a synthesis of above-presented data referring to zinc misbalances in conditions of opioid administration is
presented below
biological fluid or structure
where zinc concentration
was determined
zinc concentration evolution compared to controls and mechanisms or details (where available)
serum or plasma decreased Sadlik J. et al., 2000 (humans – in case of heroin users; tendency to normalize
upon detoxification treatment, but not reaching levels in control group) [44]
Elnimr T. et al., 1999 (humans – correlated with the abuse period) [45]
Ruiz Martinez M. et al., 1999 (humans – accompanied by increased copper) [46]
Iyengar V. et al., 1994 (humans – due to increased renal elimination) [69]
increased Floriańczyk B., 2000 (mice, morphine) [77]
red blood cells decreased Ruiz Martinez M. et al., 1999 (humans) [46]
cerebrospinal fluid decreased Potkin S.G. et al., 1982 (humans) [47]
other tissues brain decreased Floriańczyk B., 2000 (mice, morphine) [77]
Gulya K. et al., 1991 (rats) (parietal cortex, hippocampus and striatum) – induced
by the δ- agonist
(D-Pen2, D-Pen5)enkephalin, antagonized by naloxon [11]
liver increased Hidalgo J. et al., 1991 (rats, morphine) [75]
decreased Floriańczyk B., 2000 (mice, morphine) [77]
lungs, kidney decreased Floriańczyk B., 2000 (mice, morphine) [77]
heart, spleen, muscle increased Floriańczyk B., 2000 (mice, morphine) [77]
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Acute third ventricle administration of zinc in minute
amounts (3 to 300 pmol) induces a dose-dependent anti-
dipsogenic action in dehydrated rats, which is almost
complete at the highest dose. The effect is reversed by
naloxone, indicating that it is at least partially due to
stimulation of central opioid peptides [85].
Zinc deficient animals have reduced dynorphin (a
leucine-enkephalin-containing opiate peptide and a
potent inducer of spontaneous feeding) levels in the
hypothalamus compared to ad libidum-fed animals,
while weight-restricted animals exhibit intermediate
values. Zinc-deficient animals are also relatively resist-
ant to dynorphin-induced feeding. This suggests that
zinc deficiency-induced anorexia is mediated by appe-
tite deregulations of the endogenous opiate system,
which appear to include alterations in receptor affinity,
a post-receptor defect and alterations in the dynorphin
synthesis and/or release [72]. Zinc ions inhibit pro-
opiomelanocortin neurons in the hypothalamic arcuate
nucleus (vital anorexigenic neurons) [73]. Although this
fact represents a further proof of zinc-deficiency in-
duced anorexia and its opioid-mediated origin, it seems
reasonable to consider it slightly in disagreement with
the above-discussed two studies (pro-opiomelanocortin
is the precursor of the main endogenous opioids, and if
pro-opiomelanocortin neurons are inhibited by zinc, it
can be inferred that zinc reduces the level of brain-
acting opioids; the article did not evaluate the level of
extracellular opioids following zinc administration).
This proof of zinc deficiency-induced dysfunction of
opioidergic system, together with the fact that zinc
deficiency is common among opioid consumers, may
constitute a supplementary explanation for a downward
spiral: addiction and malnutrition are frequently associ-
ated; both of them are associated with zinc deficiency,
which further contributes to anorexia, by reducing re-
sponse to dynorphine-determined feeding.
zinc ions actions and zinc deficit effects on opioid
addiction or dependence
To our knowledge, there are no studies regarding zinc
ions actions and zinc deficit effects on human opioid
addiction or related conditions (tolerance, psychological
dependence, craving etc.). There are, however, two ani-
mal studies focusing on zinc salts or zinc ions deficit
on morphine dependence in rodents. Preliminary data
of ours evidenced a reduction of morphine-induced
dependence in rats by administration of ZnCl2, 0.1
and 0.05 mM/kg/day (intraperitonal), during the
10 days of morphine-dependence induction phase.
The effect is dose-dependent and we consider that it
can mainly be explained by reduced affinity of mor-
phine to specific receptors in conditions of zinc ex-
cess. Morphine dependence intensity was evaluated by
assessment of the naloxone-precipitated withdrawal
[41]. Our results are in agreement with the study of
Larson et al., [40], evidencing increased withdrawal
jumpings (but with no influence on acute dependence)
in conditions of zinc-chelator administration in mice.
Zinc ions actions and zinc deficit effects on
models of pain and on the opioid-mediated
analgesia
Human studies
Human studies about zinc influence on pain perception
are rarely available or inconsistent. There are some data in-
dicating the association between different forms of chronic
pain and zinc deficiency, and a possible beneficial role of
zinc supplementation in such cases, but overall, there is no
uncountable prove of the analgesic effect of zinc in case of
doses regularly used for oral supplementation. We have se-
lected eight studies considered to have certain relevance to
our topic and below we briefly present the data.
A clinical study revealed the association between low
plasma zinc and tongue pain, a type of neuropathic pain
[86]. Zinc levels in patients with trichodynia, a condition
associating pain and a stinging sensation of the scalp
related to diffuse alopecia, are not different compared to
controls [87]. Zinc sulfate oral administration has better
effects than placebo in alleviating dysmenorrhea [88]
and reduces, up to total suppression, the muscle pain
cramps in cirrhotic patients with hypozincemia [89].
The beneficial effect of a dietary supplement containing
lycopene, epigallocatechin gallate, ellagic acid, selenium
and zinc on chronic pelvic pain syndrome [90] and the
reduction of chronic low back pain symptoms by
alkaline minerals supplementation [91] were evidenced,
but there is no proof of the specific role of zinc in nei-
ther of these. Zinc supplementation was thought to con-
tribute to the prevention of sickle cell anaemia pain
crisis, but it has not been scientifically proven [92, 93].
In brief, the results of the mentioned eight studies can
be summaries as it follows: two of them claim the benefi-
cial role of zinc administration in different forms of
chronic pain [89, 90], two others claim that dietary supple-
ments containing zinc (among others) alleviate certain
forms of pain, but the particular role of zinc is not proven
[91, 92]. One study reports low levels of zinc in a form of
neuropathic pain [87], while another study reports that
zinc levels is no different compared to control in another
type of chronic pain [88]; two studies discuss the oppor-
tunity of zinc supplementation in sickle cell anaemia, but
there is no clear proof of the role of zinc administration in
preventing painful crisis specific to this disease [93, 94].
Animal studies
Animal studies demonstrating the analgesic effects of
non-toxic zinc doses are numerous and consistent; most
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of were performed in opioid-free animals. We have found
six studies presenting zinc ions and/or zinc chelators
effects on animal pain models in opioid-free conditions-
only, five articles presenting zinc ions or zinc chelators
effects on opioid-induced analgesia and one study evaluat-
ing the effect of zinc on pain under both opioid-free and
opioid administrating conditions.
a. zinc ions actions and zinc deficit effects on analgesia
in opioid-free animals
One of the first evidences of the analgesic effects of
zinc derives from the 1997 study on mice of Larson and
Kitto [48], demonstrating a dose-dependent effect of
intrathecal ZnCl2 in reducing the abdominal stretches
and a strong effect of ZnCl2 (10 ng, intrathecal) in redu-
cing capsaicin-induced biting and scratching behaviour
(maximal after 90 min), but lack of effect on tail-flick
latencies. Di-sodium calcium ethylenediamine tetra
acetic acid (Na+Ca2+ EDTA) reduce ZnCl2 effect on
writhing assay, and both Na+Ca2+ EDTA and dipicolinic
acid (divalent cations chelators, the latter with greater
selectivity for zinc) induce hyperalgesia in tail-flick assay,
which is antagonized by zinc in a dose dependent man-
ner in case of Na+Ca2+ EDTA.
Further studies of the same researchers (1999) indi-
cated only a modest inhibition of writhing following
intrathecal injection of high doses of zinc 24-h before
writhing-induction, suggesting that, although zinc is ne-
cessary, but it may not be sufficient to induce a long-term
antinociception. However, intrathecal co-administration of
Na+Ca2+ EDTA (10-100 nmol) or dipicolinic acid (1 nmol)
inhibited the antinociceptive effect of intrathecal capsai-
cine (2.8 nmol) or SP(1–7) (substance P) (10 nmol). None
of the chelators alone influenced the writhing test in
capsaicine- and SP(1–7)-free animals [49].
More evidences come from Liu et al., [50], revealing
that intrathecal, intraplantar or systemic injection of
ZnCl2 relieved thermal hyperalgesia in a dose-dependent
manner in rats with sciatic nerve injury, while it has no
influence on thermal nociception in the absence of
nerve injury. Higher doses are required for intraperito-
neal injections than for intrathecal or intraplantar in-
jections [50].
The 2011 study of Matsunami M. et al. showed that the
visceral nociceptive behaviour and abdominal allodynia/
hyperalgesia caused by intracolonic sodium hydrosulfide in
mice are abolished by intracolonic preadministration of
ZnCl2 and reproduced by Zn
2+ chelators. The effect of zinc
in modulating this form of visceral pain is believed to be
related to selective inhibition of T-type Ca2+ channels [51].
A very complex study of Nozaki et al. [52], revealed
sustained zinc analgesia in different mice models of pain.
Tail-flick latencies are increased following ZnCl2
intrathecal (0.2nM) and subcutaneous (0.1-1 mg/kg) ad-
ministration, the effect being maximal at 90 min. In a
model of inflammatory pain, ZnCl2 (0.2nM, intrathecal
and 1 mg/kg, subcutaneous) determined strong antino-
ciceptive effects, in both thermal and mechanical hyper-
algesia. ZnCl2 (0.2nM, intrathecal and 0.1-1 mg/kg,
subcutaneous) determined antinociceptive effects in a
model of neuropathic pain induced by sciatic nerve
ligation. It was demonstrated that zinc-induced analgesia
is dependent on high-affinity binding of zinc to the
NMDA receptor NR2A subunit, as it was completely abol-
ished in NR2A-H128S knock-in mice, where zinc inhib-
ition of NMDA currents was lost in the hippocampus and
spinal cord under both acute and chronic pain conditions
[52]. The study represents the first consistent evidence for
the mechanism of zinc-determined analgesia, a well and
long-time evidenced phenomena, which was previously
believed to be related to zinc ability to stabilize primary
afferent C-fibers.
Both zinc sulfate (0.5 and 2 mg/kg) and zinc citrate
(0.125 and 0.5 mg/kg) (intraperitoneal) induced pain
suppression in hot-plate and tail-flick tests (up to
17 %) and capsaicin writhing test (up to 25 %) in Swiss
mice [53].
Hot plate assay show the analgesic effect of zinc
oxide – conventional formulation (cZnO), 10 mg/kg,
intraperitoneal, maximal at 90 min after administration.
Zinc oxide – nanoparticals formulation (nZnO) deter-
mined higher analgesic effects compared to the conven-
tional one, pain suppression of the modern formulation
being evident at smaller doses and exhibiting a lower
latency [54]. The acute analgesic effect of both zinc
oxide formulations is antagonized by naloxone, reveal-
ing the role of endogenous opioids in zinc-analgesia.
Apart from the direct-acting mechanism of zinc as
a pain-reliever, its anti-inflammatory effect, correlated
with the pro-inflammatory status determined by zinc-
deficiency [94], should also be taken into account.
b. zinc ions actions and zinc deficit effects on analgesia
in opioid-treated animals
If there are uncountable proofs of the analgesic effect
determined by zinc ions, in case of the association of
zinc with analgesic opioids, most of the results seem at
least controversial. The relevant retrieved search results
on the interaction between zinc and analgesic opioids on
pain perception are presented below.
The first study revealing zinc interaction with opioid
analgesic effect states that Zn2+ administered intra-
thecally inhibited morphine antinociception in a dose-
related fashion, but it also inhibited the development of
acute tolerance to morphine antinociception (5 h after
100 mg/kg of morphine). However, intrathecal injection
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of Na+Ca2+ EDTA, a chelator of divalent cations, had no
effect on analgesia and acute tolerance [40].
A more recent study proves that the acute analgesic effect
(hot-plate assay) of morphine, 6 mg/kg (intraperitoneal) is
increased by ZnO nanoparticals (5 mg/kg, intraperitoneal,
co-administered with morphine), but it is not influenced by
the classical ZnO formulation (10 mg/kg, intraperitoneal)
[54]. The acute analgesic effects of 5 mg/kg nZnO and of
10 mg/kg cZnO (intraperitoneal) are antagonized by nalox-
one, 1 mg/kg, intraperitoneal co-administration, when
evaluated 60 min after co-administration [54].
Preliminary own studies show that ZnCl2 (0.05 and
0.1 mg/kg/day, intraperitoneal, 10 days, during morphine-
dependence induction) does not alter the acute effect of a
high morphine dose in tolerant rats [95].
Coordination compounds of methenkephalin with
transition metals (copper, cobalt, nickel and zinc) were
shown to be superior to morphine by the analgesic
activity and to morphine and methenkephalin by the
duration of the analgesic effect [96].
Zinc deficiency tends to lower morphine-analgesic po-
tency in mice [97].
A very recent study shows the enhancement of trama-
dol analgesic effects evaluated by tail-flick and hot-plate
assay by intraperitoneal zinc administration (increase of
approximately 30 % in the average pain inhibition com-
pared with tramadol-alone at the most effective dose,
which was 75 mg/kg b.w. zinc) in Swiss Weber male
mice [98].
Discussions
We found only two experiments focusing on the effects
of zinc ions or zinc deficit on opioid dependence and
results are accordant: zinc reduces dependence intensity
when administered during dependence induction phase,
while zinc chelators increase withdrawal manifestations
(jumpings). Both these experiments used morphine and
evaluated the intensity of naloxone-precipitated with-
drawal [40, 41]. To our knowledge, there are no clinical
studies regarding zinc influence on any type of substance-
addiction or other addiction-types.
One shortcoming of the mentioned studies (on rats
and mice) in terms of predictability for human aspects
of addiction is that they did not use self-administration
models: the doses of morphine used for dependence
induction and the moment of their administration was
established by the experimenter, and this represents a
considerable difference compared to the characteristics
of addiction in humans, where drug-taking habits have a
strong determination by social conditions. Animal models
of drugs self-administration are more predictive to human
patterns of drug-taking compared to dependence animal-
models where the drug administration is performed by ex-
ternal factors (such as the experimenter) [99]. Even more,
the predictability of such animal experimental studies to
humans is questionable, in the context of our hypothesis,
especially as zinc was given by intraperitoneal injection in
rats [41], whereas zinc salts as dietary supplements in
humans are administered orally.
Most probably, the result of cited researches [40, 41]
can be, at least partially, be put in relation with zinc ions
property of decreasing morphine-binding to receptors,
as revealed by in vitro studies. There are no specific data
showing decreased morphine receptors-binding by zinc
ions, but decreased binding of a μ-specific agonist by
zinc was demonstrated [42] and other in vitro studies
[43, 78, 79] showed reduced opioids-binding (both
agonists and antagonist) to receptors by zinc, evident
even at physiological concentration. The μ-receptors
type is particularly susceptible to this inhibition type,
but in case of δ-receptors, the number of binding sites is
also decreased, while the affinity of opioids such as pent-
azocine to the non-opioid receptor σ is un-affected by
zinc deficit [83]. The μ-type of opioid receptors-
mediated effects has the most important contribution to
addiction development [100]. Apparently in disagree-
ment with the effect of zinc of lowering opioids bio-
logical effects by decreasing their binding affinity to
receptors (evidenced by in vitro studies) are the evi-
dences from animal experiments showing a positive cor-
relation between the activity of endogenous opioids
system and zinc levels [72, 86].
The results of the mentioned animal studies showing
reduced morphine withdrawal in zinc-administrating
conditions and withdrawal enhancement by zinc chela-
tors [40, 41] suggest that a possible beneficial role of zinc
supplementation in humans taking opioid treatment for
chronic pain in reducing the risk of addiction develop-
ment or the severity of addiction and tolerance is worth
testing. Indeed, the risk of developing addiction in these
patients is low (below 10 %) [101], but tolerance to
opioids represents an important problem.
The idea of zinc supplementation in patients with ma-
lignant tumours taking opioids for pain suppression is
reinforced by human studies documenting reduced zinc
levels in opioid-users [44–47, 69]. In these patients, zinc
deficit and its consequences as an additional strain to
disease or to its associated conditions, can easily be
avoided if discovered on time. However, low levels of
zinc are mainly documented for the persons where
controlled-use (as recreational drugs of abuse) has
turned to addiction, and not for patients treated with
opioids for chronic pain or other medical purposes.
Most of the above-mentioned studies focused only on
microelements homeostasis, but not on the feeding-
habits. Opioids are known to induce side effects on the
gastrointestinal tract, such as constipation, anorexia,
vomiting, gastro-oesophageal reflux, abdominal pain
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[102] which may explain the tendency to malnutrition in
opioid-users. One study assessing the changes in nutri-
tional habits of opiates dependent persons during of
methadone maintenance treatment revealed that, before
enrolling in the treatment, the intake of calcium and
magnesium was low, whereas low zinc intake was seen
only in the women group; after four years of treatment,
low zinc intake was noticed only in the men group.
Several minerals and vitamins (such as iron, vitamins B1,
B2, C, niacin) low-intake levels were revealed both be-
fore and after treatment, but there are significant differ-
ences between genders [103]. Apart from the human
studies showing the association between decreased zinc
levels and opioid-consumption, there are animal studies
evidencing reduced brain zinc level following opioid
administration [77], while data regarding zinc serum in
opioids-treated animals are controversial [75, 77]. So, it
is not well-established if opioids induce zinc deficiency
or just altered distribution, as, on the other hand, there
are also evidences that mild zinc deficiency is not ac-
companied by reduced brain zinc in rodents, as adapta-
tion of the transporters favours the brain uptake of zinc
ions [28, 29].
Zinc deficiency, associated to the depletion of other
essential nutrients, including minerals and vitamins,
can be considered a consequence of malnutrition. Both
cancer and pain are conditions associated with the
tendency to deficient feeding [104, 105]. On the other
hand, reduced zinc level was proven to determine
impaired-feeding in animal models [72, 73], while in
humans, zinc administration alone (50 mg elemental
zinc/day) is believed to have a role in alleviating feeding-
habits in anorexia nervosa, by decreasing the level of
depression and anxiety [106]. Reduced zinc also affects
taste perception [25].
When discussing the opportunity of zinc administration
in cancer patients, it should not be disregarded that zinc
deficiency represents a predisposing factor for malignant
tumours development, as zinc depletion increases the
inflammatory status, impairs the immune system func-
tioning, antioxidant defence, and affects the DNA struc-
ture [107]. Zinc deficit is common among cancer patients,
which are also more prone to develop infections. So, zinc
has a beneficial role in infections prevention by stimu-
lating the immune system [21]. In case of cancer ther-
apy, side effects of antitumor drugs (such as vomiting,
diarrhoea) represent further factors which can favour
nutrients deficit.
Moreover, decreased zinc has a certain influence on
other mechanisms involved in the addiction downward
spiral, as it is associated with depression-like symptoms
and anxiety in both humans and animal models [26, 27],
which are known to induce drug-taking behaviour [108].
Animals studies showed reduced endogenous opioidergic
system activity following zinc depletion [72, 85]. Normal-
izing zinc level in zinc-deficient patients taking opioids for
chronic pain could have a contribution to the reduction of
the drug-seeking behaviour and of the self-administered
opioid doses by attenuating depressive symptoms and
enhancing endogenous opioidergic system activity, which
may lower the craving.
So, as suggested by animal studies, we have hypothe-
sised in the current review that zinc administration as
dietary supplement may reduce the risk of developing
dependence in patients with cancer treated with opiates
for chronic pain. Apart from the assumption above, in
the previous paragraphs, further possible benefits of
zinc supplementation in such persons are discussed. To
summarize, increasing zinc intake in these patients not
only corrects a metabolic misbalance commonly encoun-
tered in both cancer and opioid-use (which is most likely
not just a consequence of feeding-habits), but it may also
improve conditions such as tendency to malnutrition,
depressive-symptoms, anxiety, susceptibility to DNA-
damage and infections. Other clinical signs and symptoms
which would be alleviated by repletion (to which response
is believed to appear fast [20]) might include: skin lesions,
impaired night vision, altered smell and taste perception,
growth retardation, male hypogonadism, impaired wound
healing, increased inflammatory status [21–26].
Zinc low toxicity represents one more fact pleading
for zinc supplementation in opioid-users [31–33]: when
taken orally, even doses tens of times higher than rec-
ommended daily allowance determine only non-severe
manifestations, mainly digestive.
If in vitro study evidences that zinc inhibition of
opioid-agonists binding to receptors could explain, at
least in part, reduced opioid dependence under zinc-
administration conditions and withdrawal potentiating
by zinc-chelators in rodents, the same evidences also
raise the problem of decreased opioid analgesia potency
under zinc-administrating conditions. Therefore, if zinc
co-administration with opioids would decrease the risk
and the severity of dependence/addiction development ver-
sus opioid-only administration, than this might come with
the price of zinc lowering the analgesic effect of opioids. In
humans, opioid doses used for pain suppression are self-
regulated, and if zinc reduces opioid action at receptor
level, it seems logical to consider that opioid potency is also
affected, which may lead to increasing opioid administered
doses. So, the chance to reduce addiction intensity or sus-
ceptibility to addiction becomes debatable. On the other
hand, dependence is mainly mediated by μ-receptors [109],
while in analgesia δ and κ-opioid receptors are also
involved, but ligands affinity to δ and κ receptors is less
affected by zinc inhibition, as shown in vitro [42].
In order to have an idea of the extent to which zinc
might affect opioid-analgesia, the medical literature was
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searched to document the effect of zinc on pain percep-
tion in opioid-free and opioid-administrating conditions.
The search revealed scarce data derived from the human
studies. On the other hand, in animals, zinc formulations
determine, at non-toxic systemic or local doses, indubit-
able analgesic effects in different models of pain: acute
visceral, mechanical and thermal pain, under regular,
inflammatory and neuropathic conditions [48–54]. Zinc
effects on chronic pain animal models are less studied. It
is, however, questionable if zinc analgesic effect can be
additive to opioid-induced pain-suppression. In animal
models, potentiation of morphine antinociception by
zinc was evidenced in the case of a nano-particals ZnO
formulation, but classical formulation does not modify
morphine antinociception [54], while systemic zinc ad-
ministration enhances tramadol-induced analgesia [98].
Our study showed that ZnCl2 administration during
dependence-development does not alter morphine anal-
gesia in tolerant rats [96], but others proved the inhib-
ition of acute morphine antinociception by intrathecal
zinc, however accompanied by tolerance inhibition [40].
Another study claims that zinc deficiency decreases
opioid-analgesia in mice [97]. To our knowledge, in
humans, the effect of zinc on opioid-analgesia (either in
non-dependence, tolerance or addictive condition) has
not been studied. Zinc supplementation influence on the
analgesic effect of an acute opiate dose in dependent/
tolerant individuals therefore becomes therefore very
difficult to predict. Further clinical studies are needed, as
tolerance to opioid is common in patients treated with
such substances, especially the tolerance to analgesia
[101]. If indeed, there are several data pleading in the
favour of our hypothesis regarding the opportunity of
zinc supplementation in persons treated with opioid for
chronic pain suppression (such as zinc low toxicity,
reduced zinc levels following opioid use, depressive
symptoms associated with zinc deficiency, zinc lower-
ing morphine dependence documented in rats), the
problem of zinc interferences with opioid analgesia re-
mains controversial and seems to represent the main
contra-argument to the hypothesis. In case of animal
studies, the inhibition of acute tolerance to morphine
analgesia by zinc [40] was proven in mice, but it is accom-
panied by analgesia inhibition. The very few studies on
how zinc affects opioid analgesia in opioid-dependent
animals have not considered self-administration models
[40, 96], but dependence models where administration
is performed by the experimenter, whereas in humans,
analgesic opioid doses and the moment of their admin-
istration are supposed to be self-controlled. Another
problem is the lack of correspondence between doses
used in acute pain animal models, where zinc is admin-
istered parenteral, and zinc levels reached at action site
in case of oral supplementation.
We suggest a controlled clinical trial comparing the
evolution of opioid doses needed for pain-relief in
cancer patients cohorts with adequate nutrition versus
adequate nutrition associated with zinc supplementa-
tion. It is mandatory to have a survey on the nutrition,
associated drug-therapy, and environmental conditions
in case of patient groups, as all these can determine the
lack or excess of essential nutrients (including vitamins,
minerals, aminoacids etc.) and as there is a dynamic
cooperation and complex interaction and between these
nutrients.
We speculate that zinc supplementation would most
probably be beneficial for patients with cancer taking
opioids for pain therapy, where dependence is less
likely to develop, rather than for people taking them in
recreational purposes, where psychological addiction is
more frequent and severe [110]. Zinc supplementation
for patients receiving methadone or other long-acting opi-
oids maintenance treatment for opioid addiction is also
worth being considered, especially as zinc urinary elimin-
ation is increased in case of methadone treatment [69].
Zinc ions strongly influence lots of neurotransmitter
systems, including dopaminergic, glutamatergic, seroto-
ninergic system; all of these has certain roles in addic-
tion development and addiction-related phenomena, but
such influence is not discussed in this review, due to the
complexity of such a subject and to the difficulty of data
interpretation.
Conclusions
The present review pleads that a possible beneficial role
of zinc dietary supplementation in patients with malig-
nancies treated with opiates for pain-suppression should
be considered. The main arguments are: 1) reduction of
morphine-dependence intensity in an model where zinc
was administered in escalating during morphine induction
phase and potentiation of some morphine withdrawal
manifestations by the use of zinc chelators (evidenced by
animal studies); 2) reduced zinc level in opioid users; 3)
zinc own analgesic effects (well-evidenced on experimental
rodents studies and, to a lesser extent, revealed by clinical
studies); 4) the low toxicity of zinc salts for oral administra-
tion. The main contra-argument is related to the suspected
zinc effect of lowering the opioids analgesic efficacy, due
to affecting the analgesic binding to specific receptors.
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